Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures
| Autor: | R. Roncero, A M Mena, J. Pardo, F. Mestre, N. Aymar, M. Vidal, I. Ortiz, E. Jimenez |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research Visual analogue scale medicine.medical_treatment Pain Procedural Fentanyl 03 medical and health sciences 0302 clinical medicine Neoplasms Humans Medicine Aged Pain Measurement Radiotherapy procedures Aged 80 and over Radiotherapy business.industry Breakthrough Pain Cancer Pain Nasal Sprays General Medicine Middle Aged Advanced cancer Analgesics Opioid Radiation therapy 030104 developmental biology Oncology Nasal spray Treatment delivery 030220 oncology & carcinogenesis Anesthesia Female business Cancer pain medicine.drug |
| Zdroj: | Clinical and Translational Oncology. 21:1568-1572 |
| ISSN: | 1699-3055 1699-048X |
| Popis: | The aim of the study was to evaluate the effectiveness of fentanyl pectin nasal spray (FPNS) in controlling procedural breakthrough cancer pain (BTCP) in advanced cancer patients undergoing radiotherapy. This study involved 62 advanced cancer patients, with well-controlled background pain, who presented BTCP associated to routine radiotherapy procedures, treated with FPNS according to our protocol of administration. The BPE intensity was measured using a visual analog scale (VAS). The BTCP was triggered during the computed tomography simulation (79.3%) or treatment delivery (20.7%). Patients indicated a mean VAS of 8.8 (range 7–10) when attempting the procedure. After 4.5 min (range 2–10) of the first FPNS dose, the majority of patients (85.5%) indicated a VAS of 4.3 (range 2–6). 15.5% of the patients did not respond after 15 min; requiring a second dose. All these patients responded, reporting a mean VAS of 4.2 (range 4–6) after 3.0 min (range 2–5) of the second dose. None of the patients required a third dose, nor reported an AE after the administration of FPNS. In our knowledge, our study is the one of highest recruitment, and with the fastest response of BTCP treated with FPNS reported in advanced cancer patients undergoing radiotherapy. FPNS has proven to be highly effective in reducing the intensity of procedural BTCP in a very short period of time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink